A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Summary

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking participants who: Are aged 12 years or older. Were confirmed to have atopic dermatitis (AD) at least 12 months ago. Are not having an effective treatment result from medicines that are applied on skin for AD. Are considered by their doctors to have moderate to severe AD.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Atopic Dermatitis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites